Image de couverture de livre

Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT ‐ UC Consortium

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Brian C. Weiner
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium
par: Parambir S. Dulai, et autres
Publié: (2024)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
par: Ankit Kumar, et autres
Publié: (2026)

Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
par: Sarah Melton, et autres
Publié: (2025)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
par: Rónán O'Connor, et autres
Publié: (2026)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
par: Richard Pollok
Publié: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
par: Zhidong Zhou, et autres
Publié: (2025)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
par: Merle Claßen, et autres
Publié: (2024)

Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5‐Aminosalicylate for Ulcerative Colitis—The EASI Trial
par: Rie Louise Møller Nordestgaard, et autres
Publié: (2025)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis
par: Ganesh Bhat, et autres
Publié: (2026)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
par: Anish J. Kuriakose Kuzhiyanjal, et autres
Publié: (2025)

Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.
par: Aakash Desai, et autres
Publié: (2025)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
par: Amol N. Patil, et autres
Publié: (2026)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
par: Ahmed B. Bayoumy, et autres
Publié: (2025)

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
par: Arshdeep Singh, et autres
Publié: (2025)

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial
par: Ankit Kumar, et autres
Publié: (2026)

Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study
par: Tom van Gils, et autres
Publié: (2024)

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply
par: Aakash Desai, et autres
Publié: (2025)

Editorial: Striving for Equitable Care in Ulcerative Colitis
par: Edward L. Barnes
Publié: (2025)

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis
par: Silvio Danese, et autres
Publié: (2025)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
par: Antoine Meyer, et autres
Publié: (2025)

Meta‐Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis
par: Matthew K. W. Chu, et autres
Publié: (2025)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
par: Pardhu Bharath Neelam, et autres
Publié: (2025)

Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study
par: Mathilde Osty, et autres
Publié: (2025)

Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
par: Austin Haynesworth, et autres
Publié: (2024)

Editorial: Evolving Trends in Ulcerative Colitis Management—Insights From the Lothian Cohort
par: Shintaro Akiyama
Publié: (2025)

Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003–2020
par: J. Couch, et autres
Publié: (2025)

Editorial: The Appendix—A Dead End for Treating Ulcerative Colitis, After All?
par: Johan D. Söderholm
Publié: (2025)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse
par: Mark A. Ainsworth, et autres
Publié: (2025)

Letter : Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
par: Hariti Saluja, et autres
Publié: (2026)

The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis
par: Laurie‐Rose Dubé, et autres
Publié: (2026)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
par: María Chaparro, et autres
Publié: (2024)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
par: Shinichiro Shinzaki, et autres
Publié: (2025)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
par: J. Couch, et autres
Publié: (2025)

Editorial: Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis—No Surprises But the Usual Suspects Need Greater Attention
par: Weilun Gao, et autres
Publié: (2024)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
par: Dingsheng Liu, et autres
Publié: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
par: Christophe Corpechot
Publié: (2026)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
par: Jiru Li, et autres
Publié: (2025)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
par: Jeffrey D. McCurdy, et autres
Publié: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
par: J. M. Schattenberg, et autres
Publié: (2026)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor
par: Shoko Miyahara, et autres
Publié: (2025)